Ozempic, Wegovy and Rybelsus sales up steeply, especially in the U.S.
Combined annual sales for Ozempic, Wegovy and Rybelsus by region, in U.S. dollars
Note: Figures converted from Danish kroner to U.S. dollars, at rate of 1 krone = $0.154. Total 2018 and 2019 sales for Europe, Middle East and Africa include the Oceania region. The U.S. Food and Drug Administration approved Rybelsus to treat Type 2 diabetes in 2019; Wegovy was approved for weight management in 2021.
Source: Novo Nordisk annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
Source: Novo Nordisk annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
PEW RESEARCH CENTER
Ozempic, Wegovy and Rybelsus sales up steeply, especially in the U.S.
Combined annual sales for Ozempic, Wegovy and Rybelsus by region, in U.S. dollars
| Year | Total | U.S. | North America, excluding U.S. | Europe, Middle East and Africa | China | Rest of world |
|---|---|---|---|---|---|---|
| 2018 | $276,584,000 | $251,636,000 | $18,942,000 | $6,006,000 | $0 | $0 |
| 2019 | $1,738,198,000 | $1,485,946,000 | $76,230,000 | $149,226,000 | $0 | $0 |
| 2020 | $3,554,936,000 | $2,845,304,000 | $144,452,000 | $484,792,000 | $1,540,000 | $78,848,000 |
| 2021 | $6,149,066,000 | $4,434,738,000 | $269,808,000 | $1,029,028,000 | $46,662,000 | $368,830,000 |
| 2022 | $11,894,498,000 | $8,145,830,000 | $579,656,000 | $1,876,490,000 | $347,886,000 | $944,636,000 |
| 2023 | $22,454,894,000 | $15,939,000,000 | $1,021,174,000 | $3,152,688,000 | $762,608,000 | $1,579,424,000 |
| 2024 | $31,084,746,000 | $21,677,964,000 | $1,289,288,000 | $4,720,100,000 | $996,226,000 | $2,401,168,000 |
Note: Figures converted from Danish kroner to U.S. dollars, at rate of 1 krone = $0.154. Total 2018 and 2019 sales for Europe, Middle East and Africa include the Oceania region. The U.S. Food and Drug Administration approved Rybelsus to treat Type 2 diabetes in 2019; Wegovy was approved for weight management in 2021.
Source: Novo Nordisk annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
Source: Novo Nordisk annual reports, accessed through U.S. Securities and Exchange Commission’s EDGAR database.
PEW RESEARCH CENTER
